Overall survival according to risk group. Median overall survival from initiation of second-line chemotherapy was 23.5 months (95% CI, 18.7–not reached) in the low-risk group, 14.6 months (95% CI, 8.4–19.9) in the intermediate-risk group, and 5.5 months (95% CI, 4.2–8.9) in the high-risk group.